Superiority of dual IDO1/TDO2 inhibition versus IDO1 selective inhibition in reducing immunosuppressive KYN levels in tumors co-expressing IDO1 and TDO2

被引：0
|
作者：
Lotz-Jenne, Carina [1 ]
Cren, Sylvaine [1 ]
Joesch, Christoph [1 ]
Ackerknecht, Sabine [1 ]
Brandes, Jennifer [1 ]
Moebs, Claire [1 ]
Hartl, Dominik [1 ]
Hartrampf, Felix [1 ]
Guerry, Philippe [1 ]
Pothier, Julien [1 ]
Chavanton-Arpel, Alexia [1 ]
机构：
[1] Idorsia Pharmaceut Ltd, Allschwil, Switzerland
来源：
CANCER IMMUNOLOGY RESEARCH | 2022年 / 10卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B66
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Discovery of novel isothiourea derivatives as potent dual inhibitors of IDO1 and TDO
    Ogo, Naohisa
    Muraoka, Daisuke
    Ando, Takayuki
    Asai, Akira
    CANCER SCIENCE, 2021, 112 : 557 - 557
  • [22] Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO
    Kim, Minah
    Tomek, Petr
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [23] AT-0174, a novel dual IDO1/TDO2 enzyme inhibitor, synergises with temozolomide to improve survival in an orthotopic mouse model of glioblastoma
    Bickerdike, Michael J.
    Nafia, Imane
    Bessede, Alban
    Chen, Cheng-Bang
    Wangpaichitr, Medhi
    BMC CANCER, 2024, 24 (01)
  • [24] Gene Variant Frequencies of IDO1, IDO2, TDO, and KMO in Substance Use Disorder Cohorts
    Contella, Lindsey
    Farrell, Christopher L.
    Boccuto, Luigi
    Litwin, Alain
    Snyder, Marion L.
    GENES, 2024, 15 (11)
  • [25] Preclinical development of M4112, an IDO1/TDO2 dual selective and orally bioavailable small molecule inhibitor, and combination with avelumab, for treatment of solid tumors
    Chen, Jieqing
    Chu, Chia Lin
    Jiang, Feng
    Xu, Chunxiao
    Zhang, Yanping
    Yalavarthi, Sireesha
    Coop, Molly
    Wang, Hong
    Wang, Yanyan
    Hanschke, Bettina
    Siddharta, Anindya
    Zhang, Sen
    Deshpande, Amit
    Naughton, Bartholomew
    Porichis, Filippos
    Lin, Tai-An
    Halle, Joern-Peter
    Senger, Tilo
    Sherer, Brian
    Moisan, Jacques
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [26] Characterization of indoleamine-2,3-dioxygenase 1, tryptophan-2,3-dioxygenase, and Ido1/Tdo2 knockout mice
    Aslamkhan, Amy G.
    Xu, Qiuwei
    Loughlin, Amy
    Vu, Heather
    Pacchione, Stephen
    Bhatt, Bhavana
    Garfinkel, Ivy
    Styring, Tara Grady
    LaFranco-Scheuch, Lisa
    Pearson, Kara
    Reynolds, Spencer
    Li, Nianyu
    Zhou, Heather
    Miller, J. Richard
    Solban, Nicolas
    Bass, Alan
    Glaab, Warren E.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2020, 406
  • [27] Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice
    Zhang, Rongjie
    Wang, Yuanfeiyi
    Liu, Dan
    Luo, Qing
    Du, Peixin
    Zhang, Haiyan
    Wu, Wenshuang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [28] ADVANCED AGING INCREASES IMMUNOSUPPRESSIVE IDO1 LEVELS THAT ARE UNINHIBITED BY IDO1 ENZYME INHIBITOR TREATMENT IN MODELS OF GLIOBLASTOMA
    Ladomersky, Erik
    Zhai, Lijie
    Lauing, Kristen
    Qian, Jun
    Otto-Meyer, Sebastian
    Savoor, Rohan
    Wainwright, Derek
    NEURO-ONCOLOGY, 2019, 21 : 123 - 123
  • [29] Targeting IDO1 and TDO2 is crucial for the modulation of immune effector in platinum resistant non-small cell lung cancer
    Spector, Sydney
    Wu, Chunjing
    Theodore, George
    Nguyen, Jonathan Dan
    Kim, Emily
    Garcia, Ashley
    Savaraj, Niramol
    Lim, Diane
    Feun, Lynn
    Wangpaichitr, Medhi
    CANCER RESEARCH, 2023, 83 (07)
  • [30] Discovery and Characterisation of Dual Inhibitors of Tryptophan 2,3-Dioxygenase (TDO2) and Indoleamine 2,3-Dioxygenase 1 (IDO1) Using Virtual Screening
    Sari, Suat
    Tomek, Petr
    Leung, Euphemia
    Reynisson, Johannes
    MOLECULES, 2019, 24 (23):
12345